Expertise in
1
conditions

Dr. David J. Slomiany

Pediatric Hematology Oncology
5333 Hollister Ave, Suite 250, 
Goleta, CA 
Clinical Trials:Currently Recruiting for 3 Trials
Expertise in
1
conditions
5333 Hollister Ave, Suite 250, 
Goleta, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

David Slomiany is a Pediatric Hematologist Oncology provider in Goleta, California. Dr. Slomiany is highly rated in 1 condition, according to our data. His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Fanconi Anemia, Ataxia-Pancytopenia Syndrome, and Shwachman-Diamond Syndrome.

His clinical research consists of participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatric Hematology-Oncology in MN
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SelectHealth
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

5333 Hollister Ave, Suite 250, Goleta, CA 93111

Additional Areas of Focus

Dr. Slomiany has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
Enrollment Status: Recruiting
Publish Date: December 02, 2025
Intervention Type: Procedure, Other, Drug
Study Drugs: Asparaginase, Erwinia Asparaginase, Cytarabine, Daunorubicin, Dexrazoxane, Etoposide, Gemtuzumab, Gilteritinib, Liposomal Daunorubicin, Liposomal Cytarabine, Methotrexate, Mitoxantrone, Hydrocortisone
Study Phase: Phase 3
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Enrollment Status: Recruiting
Publish Date: October 24, 2025
Intervention Type: Other
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Enrollment Status: Recruiting
Publish Date: October 24, 2025
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Calaspargase, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, Inotuzumab, Leucovorin, 6-Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Thioguanine, Vincristine
Study Phase: Phase 3
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Drug, Procedure, Biological, Other, Radiation
Study Drugs: Asparaginase, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Mitoxantrone, Mitoxantrone Hydrochloride, Pegaspargase, Hydrocortisone, Thioguanine, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Other, Drug, Biological
Study Drugs: Bleomycin, Brentuximab, Cyclophosphamide, Doxorubicin, Etoposide, Methylprednisolone, Prednisone, Vincristine
Study Phase: Phase 3
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
Enrollment Status: Active_not_recruiting
Publish Date: November 26, 2025
Intervention Type: Drug, Other, Radiation
Study Drugs: Clofarabine, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Hydrocortisone Sodium Succinate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Drug, Other, Procedure
Study Drugs: Cisplatin, Dexrazoxane, Doxorubicin Hydrochloride, Fluorouracil, Irinotecan Hydrochloride, Temsirolimus, Vincristine Sulfate
Study Phase: Phase 3
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Drug, Biological, Radiation
Study Drugs: Erwinia Asparaginase, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Prednisone, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
Neuroblastoma Biology Studies
Neuroblastoma Biology Studies
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2025
Intervention Type: Other
Renal Tumors Classification, Biology, and Banking Study
Renal Tumors Classification, Biology, and Banking Study
Enrollment Status: Active_not_recruiting
Publish Date: March 25, 2025
Intervention Type: Other
View 7 Less Clinical Trials
Similar Doctors
Expertise in
0
conditions
Dr. Shivani Y. Upadhyay
Pediatric Hematology Oncology
Expertise in
0
conditions
Dr. Shivani Y. Upadhyay
Pediatric Hematology Oncology

Cottage Medical Foundation

4360 E Main St, Suite B2 A, 
Ventura, CA 
 (35.0 miles away)
805-879-4240
Languages Spoken:
English
See accepted insurances

Shivani Upadhyay is a Pediatric Hematologist Oncology provider in Ventura, California. Her top areas of expertise are Juvenile Myelomonocytic Leukemia (JMML), Anemia, Acute Lymphoblastic Leukemia (ALL), and Fanconi Anemia.

Expertise in
0
conditions
Dr. Asneha S. Iqbal
Pediatric Hematology Oncology
Expertise in
0
conditions
Dr. Asneha S. Iqbal
Pediatric Hematology Oncology

Cottage Medical Foundation

5333 Hollister Ave, Suite 250, 
Goleta, CA 
 (0.1 miles away)
805-879-4240
Experience:
17+ years
Languages Spoken:
English
See accepted insurances

Asneha Iqbal is a Pediatric Hematologist Oncology provider in Goleta, California. Dr. Iqbal has been practicing medicine for over 17 years. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, and Immune Thrombocytopenic Purpura (ITP).

Expertise in
0
conditions
Dr. Joseph P. Woodard
Pediatric Hematology Oncology
Expertise in
0
conditions
Dr. Joseph P. Woodard
Pediatric Hematology Oncology
1 Amgen Center Dr, Ms: 38-3-a, 
Thousand Oaks, CA 
 (53.5 miles away)
805-447-2339
Languages Spoken:
English

Joseph Woodard is a Pediatric Hematologist Oncology provider in Thousand Oaks, California. His top area of expertise is Immune Thrombocytopenic Purpura (ITP).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Slomiany's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile